Detail akcie PureTech Health online

Business Summary: PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Puretech Health PLC revenues decreased 4% to $4.7M. Net loss applicable to common stockholders totaled $109.7M vs. income of $53.5M. Revenues reflect Wholly-Owned Programs segment decrease from $513K to $0K. Net loss reflects Wholly-Owned Programs segment loss increase of 3% to $67.3M. Basic Earnings per Share excluding Extraordinary Items decreased from $0.21 to -$0.46.